Bay Colony Advisory Group Inc d b a Bay Colony Advisors Cuts Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 764 shares of the medical equipment provider’s stock after selling 161 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Intuitive Surgical were worth $258,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ISRG. Baystate Wealth Management LLC raised its stake in shares of Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 45 shares during the period. Atticus Wealth Management LLC raised its stake in shares of Intuitive Surgical by 85.4% in the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 41 shares during the period. OFI Invest Asset Management purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at $25,000. Headinvest LLC purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at $28,000. Finally, Stone House Investment Management LLC raised its stake in shares of Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Truist Financial raised their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Royal Bank of Canada raised their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Mizuho raised their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Barclays raised their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Finally, Piper Sandler raised their price target on shares of Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $375.70.

Insider Transactions at Intuitive Surgical

In other news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the transaction, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $393.80, for a total value of $7,992,564.80. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now owns 110 shares in the company, valued at $43,677.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,418 shares of company stock worth $95,927,097. 0.80% of the stock is currently owned by insiders.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $378.55 on Wednesday. The firm’s 50-day moving average is $387.90 and its 200-day moving average is $342.17. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The company has a market cap of $134.18 billion, a P/E ratio of 75.26, a PEG ratio of 5.86 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same period last year, the firm posted $0.91 EPS. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.